JP2023508174A5 - - Google Patents
Info
- Publication number
- JP2023508174A5 JP2023508174A5 JP2022539176A JP2022539176A JP2023508174A5 JP 2023508174 A5 JP2023508174 A5 JP 2023508174A5 JP 2022539176 A JP2022539176 A JP 2022539176A JP 2022539176 A JP2022539176 A JP 2022539176A JP 2023508174 A5 JP2023508174 A5 JP 2023508174A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody according
- antibody
- fgfr2b
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019127904 | 2019-12-24 | ||
| CNPCT/CN2019/127904 | 2019-12-24 | ||
| PCT/CN2020/138659 WO2021129672A1 (en) | 2019-12-24 | 2020-12-23 | Novel anti-fgfr2b antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023508174A JP2023508174A (ja) | 2023-03-01 |
| JP2023508174A5 true JP2023508174A5 (enExample) | 2024-01-05 |
| JP7692419B2 JP7692419B2 (ja) | 2025-06-13 |
Family
ID=76575671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539176A Active JP7692419B2 (ja) | 2019-12-24 | 2020-12-23 | 新規抗ＦＧＦＲ２ｂ抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230052680A1 (enExample) |
| EP (1) | EP4081547A4 (enExample) |
| JP (1) | JP7692419B2 (enExample) |
| KR (1) | KR20220119144A (enExample) |
| CN (1) | CN114846029A (enExample) |
| AR (1) | AR120886A1 (enExample) |
| AU (1) | AU2020412088A1 (enExample) |
| CA (1) | CA3160812A1 (enExample) |
| MX (1) | MX2022007961A (enExample) |
| TW (1) | TWI861326B (enExample) |
| WO (1) | WO2021129672A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7686000B2 (ja) * | 2019-12-24 | 2025-05-30 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | 新規抗ＦＧＦＲ２ｂ抗体 |
| CN119110806A (zh) * | 2022-03-28 | 2024-12-10 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| CN121039158A (zh) * | 2023-03-31 | 2025-11-28 | 杭州中美华东制药有限公司 | 新型抗fgfr2抗体 |
| CN118852431A (zh) * | 2023-04-28 | 2024-10-29 | 武汉人福创新药物研发中心有限公司 | 抗FGFR2b单抗 |
| WO2024240107A1 (zh) * | 2023-05-19 | 2024-11-28 | 广东东阳光药业股份有限公司 | 一种抗fgfr2抗体及其应用 |
| TW202540177A (zh) * | 2023-11-14 | 2025-10-16 | 大陸商蘇州創勝醫藥集團有限公司 | 抗－ＦＧＦＲ２ｂ免疫偶聯物及其於治療癌症的用途 |
| WO2025130905A1 (zh) * | 2023-12-18 | 2025-06-26 | 山东先声生物制药有限公司 | 抗FGFR2b抗体-药物缀合物及其应用 |
| JP2026508860A (ja) * | 2024-01-05 | 2026-03-13 | ビーワン メディシンズ ワン ゲーエムベーハー | 抗ＦＧＦＲ２ｂ抗体、コンジュゲート、及び使用方法 |
| CN120424212A (zh) * | 2024-01-26 | 2025-08-05 | 上海安领科生物医药有限公司 | 抗FGFR2b抗体及抗体药物偶联物 |
| CN118772279B (zh) * | 2024-06-28 | 2025-03-25 | 北京普利米特生物科技有限公司 | 抗FGFR2b抗体或其抗原结合片段及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7357928B2 (en) * | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| HUE035700T2 (en) * | 2008-11-07 | 2018-05-28 | Galaxy Biotech Llc | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
| CN105263962B (zh) * | 2013-03-19 | 2019-12-31 | 北京盛诺基医药科技股份有限公司 | 抗体及用于治疗与雌激素受体相关疾病的方法 |
| KR102516152B1 (ko) * | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| MX2018006181A (es) | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
| PT3624837T (pt) * | 2017-05-16 | 2025-10-01 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro |
-
2020
- 2020-12-23 KR KR1020227025532A patent/KR20220119144A/ko active Pending
- 2020-12-23 EP EP20904516.0A patent/EP4081547A4/en active Pending
- 2020-12-23 CN CN202080090068.7A patent/CN114846029A/zh active Pending
- 2020-12-23 WO PCT/CN2020/138659 patent/WO2021129672A1/en not_active Ceased
- 2020-12-23 AR ARP200103630A patent/AR120886A1/es unknown
- 2020-12-23 CA CA3160812A patent/CA3160812A1/en active Pending
- 2020-12-23 JP JP2022539176A patent/JP7692419B2/ja active Active
- 2020-12-23 US US17/788,733 patent/US20230052680A1/en active Pending
- 2020-12-23 MX MX2022007961A patent/MX2022007961A/es unknown
- 2020-12-23 AU AU2020412088A patent/AU2020412088A1/en active Pending
- 2020-12-24 TW TW109145975A patent/TWI861326B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508174A5 (enExample) | ||
| JP2023509402A5 (enExample) | ||
| JP2023508173A5 (enExample) | ||
| JP7820383B2 (ja) | グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド | |
| RU2749110C2 (ru) | Новый полипептид с аффинностью к PD-L1 | |
| CN110627906A (zh) | 抗pd-l1/4-1bb双特异性抗体及其用途 | |
| CN119818671A (zh) | 抗SIRPα抗体及其用途 | |
| JP7821159B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| CA2959671C (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
| JP2024500920A5 (enExample) | ||
| JP7830621B2 (ja) | 抗－ｂ７－ｈ４／抗－４－１ｂｂ二重特異的抗体およびこれの用途 | |
| JP2024001073A5 (enExample) | ||
| CN119173540A (zh) | 多特异性抗体及其用途 | |
| CN121909212A (zh) | 抗cdh17抗体及其用途 | |
| CA3208368A1 (en) | Vegfa-binding molecules | |
| JP2024020436A (ja) | Ｈｅｒ２標的化剤 | |
| JP7821161B2 (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| JP2022505144A5 (enExample) | ||
| CN112823168A (zh) | 结合her2的四聚体多肽 | |
| CN117304324A (zh) | 结合Claudin 18.2的结合部分及其应用 | |
| CN117304323A (zh) | 结合Claudin 18.2的结合部分及其应用 | |
| CN120271715A (zh) | 抗体及其药物偶联物和用途 | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| WO2025117871A1 (en) | Bispecific tetravalent antibody targeting her2 and her3 | |
| CN120379695A (zh) | 使用Multabody治疗化疗抗性肿瘤 |